SCHEMBL4152829

SCHEMBL4152829

ClCc1nc2ccccc2n1C1CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.53
MEN1 O00255 1/20 0.53
CYP11B2 P19099 2/20 0.49
OPRM1 P35372 1/20 0.47
OPRD1 P41143 1/20 0.47
OPRK1 P41145 1/20 0.47
OPRL1 P41146 1/20 0.47
OGFRL1 Q5TC84 1/20 0.47
RPS6KB1 P23443 4/20 0.47
ROCK1 Q13464 4/20 0.47
TP53 P04637 1/20 0.46
CYP11B1 P15538 1/20 0.43
DDB1 Q16531 1/20 0.42
CRBN Q96SW2 1/20 0.42
CYP2D6 P10635 1/20 0.42
CCR5 P51681 1/20 0.42
PRKACA P17612 3/20 0.42
GSK3B P49841 3/20 0.42
LMNA P02545 3/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31267382 0.93 TP53 (0.54) KMT2AMEN1OPRM1OPRD1OPRK1
SCHEMBL29135537 0.92 TP53 (0.56) KMT2AMEN1OPRM1OPRD1OPRK1
SCHEMBL30662377 0.92 TP53 (0.56) KMT2AMEN1OPRM1OPRD1OPRK1
SCHEMBL31267395 0.89 MEN1 (0.43) KMT2AMEN1CYP11B2OPRM1OPRD1
SCHEMBL22623697 0.85 LMNA (0.50) KMT2AMEN1CYP11B2OPRM1OPRD1
SCHEMBL4792097 0.85 OPRM1 (0.62) KMT2ACYP11B2OPRM1OPRD1OPRK1
SCHEMBL12776005 0.81 KMT2A (0.52) KMT2AMEN1CYP11B2OPRM1OPRD1
SCHEMBL8293608 0.79 OGFRL1 (0.53) OPRM1OPRD1OPRK1OPRL1OGFRL1
SCHEMBL31267438 0.79 OPRM1 (0.67) OPRM1OPRD1OPRK1OPRL1OGFRL1
SCHEMBL2635863 0.79 SMN1; SMN2 (0.53) CYP11B2OPRM1OPRD1OPRK1OPRL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9221836-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-12-29 US disclosed
US-20150191486-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-07-09 US disclosed
US-20090192169-A1 Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators ASTRAZENECA AB (SE) 2009-07-30 US disclosed
US-20090192169-A1 Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators ASTRAZENECA AB (SE) 2009-07-30 US disclosed
US-20090192169-A1 Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators ASTRAZENECA AB (SE) 2009-07-30 US disclosed
WO-2007115077-A2 BICYCLIC BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS ASTRAZENECA AB (SE) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192169-A1 Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators GRM1, GRIN1, GRM2 KMT2A 1865/4885MEN1 3345/4885CYP11B2 1348/4885
US-20150191486-A1 HETEROCYCLIC COMPOUND AND USE THEREOF REN, AGT, ACE KMT2A 1804/4885MEN1 990/4885CYP11B2 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.